Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients

NCT00284687 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Cytomegalovirus Infections

Interventions

DRUG: Artesunate

Sponsor

Hadassah Medical Organization

Collaborators

[object Object]
[object Object]